Compile Data Set for Download or QSAR
Report error Found 35 Enz. Inhib. hit(s) with all data for entry = 665
TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286009(US10081623, Example 22 | (E/Z)-(+/-)-Methyl N-[8-(...)
Affinity DataKi: <5nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286021(US10081623, Example 34 | (E)-Methyl N-[8-({2-[5-ch...)
Affinity DataKi: <5nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286012(US10081623, Example 25 | (E)-Methyl N-[8-({2-[5-ch...)
Affinity DataKi: <5nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286020(US10081623, Example 33 | (E)-(+/-)-Methyl N-[8-({2...)
Affinity DataKi:  6.24nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286008(US10081623, Example 21)
Affinity DataKi:  14.1nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286019(US10081623, Example 32 | (Z)-(+/-)-Methyl N-[8-({2...)
Affinity DataKi:  17.4nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM285988(US10081623, Example 1 | (+/-)-Methyl N-[8-({2-[5-c...)
Affinity DataKi:  17.9nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286000(US10081623, Example 13)
Affinity DataKi:  34.3nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286014(US10081623, Example 27 | (E/Z)-(+/-)-N-{2-[5-Chlor...)
Affinity DataKi:  39.1nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM285990(US10081623, Example 3 | Methyl N-[8-({2-[5-chloro-...)
Affinity DataKi:  41.9nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286005(US10081623, Example 18 | Methyl N-[8-({2-[5-chloro...)
Affinity DataKi:  54.3nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286013(US10081623, Example 26)
Affinity DataKi:  64.1nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286003(US10081623, Example 16 | (+/-)-Methyl N-[8-({2-[5-...)
Affinity DataKi:  73.2nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM285998(US10081623, Example 11 | (+/-)-Methyl N-[8-({2-[5...)
Affinity DataKi:  73.6nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM285999(US10081623, Example 12 | Methyl N-[8-({2-[5-chloro...)
Affinity DataKi:  81.8nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286004(US10081623, Example 17)
Affinity DataKi:  104nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286011(US10081623, Example 24)
Affinity DataKi:  153nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286010(US10081623, Example 23 | (Z)-Methyl N-[8-({2-[5-c...)
Affinity DataKi:  157nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286022(US10081623, Example 35)
Affinity DataKi:  216nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286001(US10081623, Example 14)
Affinity DataKi:  336nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286015(US10081623, Example 28 | (+/-)-N-{2-[5-Chloro-2-(1...)
Affinity DataKi:  338nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286006(US10081623, Example 19)
Affinity DataKi:  596nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM285993(US10081623, Example 6 | (+/-)-Methyl N-(8-{[2-(1-c...)
Affinity DataKi:  627nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM285994(US10081623, Example 7 | (+/-)-Methyl N-{2,10-dioxo...)
Affinity DataKi:  708nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286018(US10081623, Example 31 | (E)-(+/-)-N-(1-Carbamimid...)
Affinity DataKi:  811nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286002(US10081623, Example 15)
Affinity DataKi:  812nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM285992(US10081623, Example 5 | (+/-)-Methyl N-(8-{[(1-car...)
Affinity DataKi:  825nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM285995(US10081623, Example 8 | (+/-)-Methyl N-(8-{[(5-chl...)
Affinity DataKi:  1.34E+3nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286016(US10081623, Example 29 | (E/Z)-(+/-)-N-[(1-Carbami...)
Affinity DataKi:  1.41E+3nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM285991(US10081623, Example 4 | (+/-)-Methyl N-{8-[(1-carb...)
Affinity DataKi:  1.50E+3nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM285996(US10081623, Example 9 | (+/-)-Methyl N-{8-[3-(3-ch...)
Affinity DataKi:  2.07E+3nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM285989(US10081623, Example 2 | Methyl N-[8-({2-[5-chloro-...)
Affinity DataKi:  2.18E+3nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286017(US10081623, Example 30 | (Z)-(+/-)-N-(1-Carbamimid...)
Affinity DataKi:  2.20E+3nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM285997(US10081623, Example 10 | (+/-)-Methyl N-{8-[3-(3-m...)
Affinity DataKi:  2.62E+3nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM286007(US10081623, Example 20)
Affinity DataKi:  9.29E+3nMpH: 7.4Assay Description:The effectiveness of compounds of the present invention as inhibitors of the coagulation Factors XIa, VIIa, IXa, Xa, XIIa, plasma kallikrein or throm...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/12/2019
Entry Details
Go to US Patent